Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infectious Agents and Cancer
Published in: Infectious Agents and Cancer 1/2023

Open Access 01-12-2023 | Kaposi's Sarcoma-Associated Herpesvirus | Research

Comparison of Epstein–Barr virus and Kaposi’s sarcoma-associated herpesvirus viral load in peripheral blood mononuclear cells and oral fluids of HIV-negative individuals aged 3–89 years from Uganda

Authors: Angela Nalwoga, Vickie Marshall, Wendell Miley, Nazzarena Labo, Denise Whitby, Robert Newton, Rosemary Rochford

Published in: Infectious Agents and Cancer | Issue 1/2023

Login to get access

Abstract

We previously found that age, sex and malaria were associated with KSHV in individuals from Uganda. In this study, we have evaluated these same factors in relation to EBV in the same specimens. Overall, 74% (oral fluids) and 46% (PBMCs) had detectable EBV. This was significantly higher than observed for KSHV (24% oral fluids and 11% PBMCs). Individuals with EBV in PBMCs were more likely to have KSHV in PBMCs (P = 0.011). The peak age for detection of EBV in oral fluids was 3–5 years while that of KSHV was 6–12 years. In PBMCs, there was a bimodal peak age for detection of EBV (at 3–5 years and 66 + years) while for KSHV there was a single peak at 3–5 years. Individuals with malaria had higher levels of EBV in PBMCs compared to malaria-negative individuals (P = 0.002). In summary, our results show that younger age and malaria are associated with higher levels of EBV and KSHV in PBMCs suggesting malaria impacts immunity to both gamma-herpesviruses.
Appendix
Available only for authorised users
Literature
1.
Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt B):1–441.
2.
3.
4.
Mack AA, Sugden B. EBV is necessary for proliferation of dually infected primary effusion lymphoma cells. Can Res. 2008;68(17):6963–8.CrossRef
5.
Rochford R. Epstein-Barr virus infection of infants: implications of early age of infection on viral control and risk for Burkitt lymphoma. Bol Med Hosp Infant Mex. 2016;73(1):41–6.PubMed
6.
Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, Ploutz-Snyder R, et al. Early age at time of primary Epstein–Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis. 2012;205(6):906–13.CrossRefPubMedPubMedCentral
7.
Sabourin KR, Daud I, Ogolla S, Labo N, Miley W, Lamb M, Newton R, et al. Malaria is associated with Kaposi sarcoma-associated herpesvirus seroconversion in a cohort of western Kenyan children. J Infect Dis. 2021;224(2):303–11.CrossRefPubMed
8.
Aalam F, Nabiee R, Castano JR, Totonchy J. Analysis of KSHV B lymphocyte lineage tropism in human tonsil reveals efficient infection of CD138+ plasma cells. PLoS Pathog. 2020;16(10):e1008968.CrossRefPubMedPubMedCentral
9.
Shannon-Lowe C, Rowe M. Epstein Barr virus entry; kissing and conjugation. Curr Opin Virol. 2014;4:78–84.CrossRefPubMed
10.
Dedicoat M, Newton R, Alkharsah KR, Sheldon J, Szabados I, Ndlovu B, Page T, et al. Mother-to-child transmission of human herpesvirus-8 in South Africa. J Infect Dis. 2004;190(6):1068–75.CrossRefPubMed
11.
Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996;6(10):986–94.CrossRefPubMed
12.
Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, Matsuyama T, et al. Quantitative analysis of Epstein–Barr virus load by using a real-time PCR assay. J Clin Microbiol. 1999;37(1):132–6.CrossRefPubMedPubMedCentral
13.
Nalwoga A, Nakibuule M, Marshall V, Miley W, Labo N, Cose S, Whitby D, et al. Risk factors for Kaposi’s sarcoma-associated herpesvirus DNA in blood and in saliva in rural Uganda. Clin Infect Dis. 2020;71(4):1055–62.CrossRefPubMed
14.
Haq IU, Dalla Pria A, Papanastasopoulos P, Stegmann K, Bradshaw D, Nelson M, Bower M. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients. HIV Med. 2016;17(1):56–61.CrossRefPubMed
15.
Min J, Katzenstein DA. Detection of Kaposi’s sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi’s sarcoma, CD4 cell count, and HIV RNA levels. AIDS Res Hum Retroviruses. 1999;15(1):51–5.CrossRefPubMed
16.
Quinlivan EB, Zhang C, Stewart PW, Komoltri C, Davis MG, Wehbie RS. Elevated virus loads of Kaposi’s sarcoma-associated human herpesvirus 8 predict Kaposi’s sarcoma disease progression, but elevated levels of human immunodeficiency virus type 1 do not. J Infect Dis. 2002;185(12):1736–44.CrossRefPubMed
17.
Martró E, Cannon MJ, Dollard SC, Spira TJ, Laney AS, Ou CY, Pellett PE. Evidence for both lytic replication and tightly regulated human herpesvirus 8 latency in circulating mononuclear cells, with virus loads frequently below common thresholds of detection. J Virol. 2004;78(21):11707–14.CrossRefPubMedPubMedCentral
18.
Ito Y, Suzuki M, Kawada J, Kimura H. Diagnostic values for the viral load in peripheral blood mononuclear cells of patients with chronic active Epstein–Barr virus disease. J Infect Chemother. 2016;22(4):268–71.CrossRefPubMed
19.
Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, Valsamakis A. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–17.CrossRefPubMedPubMedCentral
20.
Nalwoga A, Nakibuule M, Marshall V, Miley W, Labo N, Cose S, Whitby D, et al. Risk factors for Kaposi’s sarcoma associated herpesvirus (KSHV) DNA in blood and in saliva in rural Uganda. Clin Infect Dis. 2019;77:543–8.
21.
Labo N, Marshall V, Miley W, Davis E, McCann B, Stolka KB, Ndom P, et al. Mutual detection of Kaposi’s sarcoma-associated herpesvirus and Epstein–Barr virus in blood and saliva of Cameroonians with and without Kaposi’s sarcoma. Int J Cancer J Int Cancer. 2019;145(9):2468–77.CrossRef
22.
Newton R, Labo N, Wakeham K, Miley W, Asiki G, Johnston WT, Whitby D. Kaposi’s sarcoma associated herpesvirus in a rural Ugandan cohort: 1992–2008. J Infect Dis. 2017;217:263–9.CrossRefPubMedCentral
23.
Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, Kazura J, et al. Exposure to holoendemic malaria results in elevated Epstein–Barr virus loads in children. J Infect Dis. 2005;191(8):1233–8.CrossRefPubMed
24.
Daud II, Ogolla S, Amolo AS, Namuyenga E, Simbiri K, Bukusi EA, Ng’ang’a ZW, et al. Plasmodium falciparum infection is associated with Epstein–Barr virus reactivation in pregnant women living in malaria holoendemic area of Western Kenya. Matern Child Health J. 2015;19(3):606–14.CrossRefPubMedPubMedCentral
25.
Yuan CC, Miley W, Waters D. A quantification of human cells using an ERV-3 real time PCR assay. J Virol Methods. 2001;91(2):109–17.CrossRefPubMed
26.
de Sanjose S, Marshall V, Sola J, Palacio V, Almirall R, Goedert JJ, Bosch FX, et al. Prevalence of Kaposi’s sarcoma-associated herpesvirus infection in sex workers and women from the general population in Spain. Int J Cancer J Int Cancer. 2002;98(1):155–8.CrossRef
27.
Newton R, Labo N, Wakeham K, Marshall V, Roshan R, Nalwoga A, Sebina I, et al. Determinants of gammaherpesvirus shedding in saliva among Ugandan children and their mothers. J Infect Dis. 2018;218(6):892–900.CrossRefPubMedPubMedCentral
28.
Labo N, Miley W, Marshall V, Gillette W, Esposito D, Bess M, Turano A, et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog. 2014;10(3):e1004046.CrossRefPubMedPubMedCentral
29.
Mbisa GL, Miley W, Gamache CJ, Gillette WK, Esposito D, Hopkins R, Busch MP, et al. Detection of antibodies to Kaposi’s sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods. 2010;356(1–2):39–46.CrossRefPubMedPubMedCentral
30.
31.
32.
33.
34.
Kafuko GW, Burkitt DP. Burkitt’s lymphoma and malaria. Int J Cancer J Int Cancer. 1970;6(1):1–9.CrossRef
35.
Robbiani DF, Bothmer A, Callen E, Reina-San-Martin B, Dorsett Y, Difilippantonio S, Bolland DJ, et al. AID is required for the chromosomal breaks in c-myc that lead to c-myc/IgH translocations. Cell. 2008;135(6):1028–38.CrossRefPubMedPubMedCentral
36.
Summerauer AM, Jäggi V, Ogwang R, Traxel S, Colombo L, Amundsen E, Eyer T, et al. Epstein–Barr virus and malaria upregulate AID and APOBEC3 enzymes, but only AID seems to play a major mutagenic role in Burkitt lymphoma. Eur J Immunol. 2022;52:1273–84.CrossRefPubMedPubMedCentral
37.
Torgbor C, Awuah P, Deitsch K, Kalantari P, Duca KA, Thorley-Lawson DA. A multifactorial role for P. falciparum malaria in endemic Burkitt’s lymphoma pathogenesis. PLoS Pathog. 2014;10(5):e1004170.CrossRefPubMedPubMedCentral
38.
Reynaldi A, Schlub TE, Chelimo K, Sumba PO, Piriou E, Ogolla S, Moormann AM, et al. Impact of Plasmodium falciparum coinfection on longitudinal Epstein–Barr virus kinetics in Kenyan children. J Infect Dis. 2016;213(6):985–91.CrossRefPubMed
Metadata
Title
Comparison of Epstein–Barr virus and Kaposi’s sarcoma-associated herpesvirus viral load in peripheral blood mononuclear cells and oral fluids of HIV-negative individuals aged 3–89 years from Uganda
Authors
Angela Nalwoga
Vickie Marshall
Wendell Miley
Nazzarena Labo
Denise Whitby
Robert Newton
Rosemary Rochford
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2023
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-023-00516-9

Other articles of this Issue 1/2023

Infectious Agents and Cancer 1/2023 Go to the issue

Research

Identification of novel miRNAs potentially involved in the pathogenesis of adult T-cell leukemia/lymphoma using WGCNA followed by RT-qPCR test of hub genes

Correction

Correction: Do women with high-risk HPV E6/E7 mRNA test positivity and NILM cytology need colposcopy?

Research

Validation in Zambia of a cervical screening strategy including HPV genotyping and artificial intelligence (AI)-based automated visual evaluation

Research

Epidemiology and survival outcomes of HIV-associated cervical cancer in Nigeria

Research

Microendoscopy in vivo for the pathological diagnosis of cervical precancerous lesions and early cervical cancer

Research

Epstein–Barr virus (EBV) antibody changes over time in a general population cohort in rural Uganda, 1992–2008
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits